Pertuzumab
Information
- Drug Name
- Pertuzumab
- Description
- Entry(CIViC)
- 14
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 5 | 25693012 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22149875 | Detail |
| lung non-small cell carcinoma |
ERBB3 p.Val855Ala (p.V855A) ( ENST00000267101.8, ENST00000415288.6, ENST00000683018.1, ENST00000683059.1, ENST00000683164.1 ) ERBB3 p.Val855Ala (p.V855A) ( ENST00000683164.1, ENST00000683018.1, ENST00000267101.8, ENST00000415288.6, ENST00000683059.1 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26689995 | Detail |
| Anaplastic thyroid carcinoma |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 29320312 | Detail |
| lung non-small cell carcinoma | ERBB2 MUTATION ERBB2 MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 29320312 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 29320312 | Detail |
| bladder carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29320312 | Detail |
| biliary tract cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| salivary gland carcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| pancreatic cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| uterine cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response |
N/A
|
2 | 29320312 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 30857956 | Detail |
| cholangiocarcinoma |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31453370 | Detail |
| pancreatic ductal adenocarcinoma | ERBB3 EXPRESSION ERBB3 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 25216528 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| CLEOPATRA (NCT00567190) was a Phase III, randomize... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a randomized phase 3 trial, HER2 positive metas... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Case report on a novel V855A mutation located in e... | ERBB3 |
ERBB3 p.Val855Ala (p.V855A) ( ENST00000267101.8, ENST00000415288.6, ENST00000683018.1, ENST00000683059.1, ENST00000683164.1 ) ERBB3 p.Val855Ala (p.V855A) ( ENST00000683164.1, ENST00000683018.1, ENST00000267101.8, ENST00000415288.6, ENST00000683059.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 | ERBB2 MUTATION ERBB2 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The phase 2a MyPathway study assigned patients wit... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | false | CIViC Evidence | detail |
| In update report of a phase 2 trial, Patients with... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| A patient with cholangiocarcinoma harboring with E... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In mice xenografts expressing ERBB3 (HER3) the com... | ERBB3 | ERBB3 EXPRESSION ERBB3 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02003209 | Active, not recruiting | Phase 3 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | January 15, 2014 | December 31, 2024 |
| NCT02320435 | Active, not recruiting | Phase 3 | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | February 2, 2015 | December 31, 2025 |
| NCT02326974 | Active, not recruiting | Phase 2 | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | January 2015 | January 2028 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT02339532 | Active, not recruiting | Phase 2 | Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status | January 2015 | June 2024 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT04538742 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer | December 28, 2020 | January 31, 2025 |
| NCT02390427 | Active, not recruiting | Phase 1 | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | April 20, 2015 | May 2024 |
| NCT05426486 | Active, not recruiting | Phase 2/Phase 3 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | May 23, 2022 | December 30, 2028 |
| NCT02436993 | Active, not recruiting | Phase 2 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | April 2015 | June 2024 |
| NCT05954143 | Active, not recruiting | Phase 2 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | November 30, 2023 | March 2025 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT04425018 | Active, not recruiting | Phase 2 | MARGetuximab Or Trastuzumab (MARGOT) | July 13, 2020 | July 1, 2027 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT01730833 | Active, not recruiting | Phase 2 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | July 17, 2013 | December 31, 2024 |
| NCT04398914 | Active, not recruiting | Phase 2 | Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | May 30, 2020 | December 30, 2027 |
| NCT06136897 | Active, not recruiting | Phase 2 | Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) | March 13, 2017 | June 24, 2024 |
| NCT05113251 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | October 25, 2021 | April 30, 2027 |
| NCT01796197 | Active, not recruiting | Phase 2 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | August 2013 | July 2024 |
| NCT04208178 | Active, not recruiting | Phase 3 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | July 16, 2020 | September 16, 2024 |
| NCT04188548 | Active, not recruiting | Phase 1 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | December 10, 2019 | December 2027 |
| NCT05574881 | Active, not recruiting | Phase 1/Phase 2 | Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer | September 1, 2022 | January 1, 2025 |
| NCT02625441 | Active, not recruiting | Phase 3 | Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer | December 2015 | June 2025 |
| NCT01937117 | Active, not recruiting | Phase 2 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | January 30, 2014 | May 2025 |
| NCT04172259 | Active, not recruiting | Phase 2 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | January 10, 2019 | September 30, 2026 |
| NCT01358877 | Active, not recruiting | Phase 3 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | November 8, 2011 | November 28, 2024 |
| NCT02205047 | Active, not recruiting | Phase 2 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma | July 15, 2015 | December 31, 2028 |
| NCT02827877 | Active, not recruiting | Phase 2 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | July 15, 2016 | December 30, 2024 |
| NCT04784715 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | April 26, 2021 | December 30, 2029 |
| NCT02947685 | Active, not recruiting | Phase 3 | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | June 21, 2017 | July 31, 2026 |
| NCT03006172 | Active, not recruiting | Phase 1 | To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer | December 13, 2016 | November 30, 2024 |
| NCT03101748 | Active, not recruiting | Phase 1/Phase 2 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | January 29, 2018 | January 1, 2026 |
| NCT02252887 | Active, not recruiting | Phase 2 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | January 12, 2015 | September 2024 |
| NCT03125928 | Active, not recruiting | Phase 2 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | June 13, 2017 | December 2024 |
| NCT05825781 | Active, not recruiting | Phase 1 | Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man | July 20, 2023 | June 2024 |
| NCT04158258 | Active, not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | February 21, 2020 | November 28, 2025 | |
| NCT03199885 | Active, not recruiting | Phase 3 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | April 5, 2019 | May 15, 2025 |
| NCT03747120 | Active, not recruiting | Phase 2 | Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab | January 25, 2019 | July 2025 |
| NCT03304080 | Active, not recruiting | Phase 1/Phase 2 | Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | December 20, 2017 | December 2024 |
| NCT03716180 | Active, not recruiting | Phase 1 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | November 5, 2018 | September 1, 2030 |
| NCT03365882 | Active, not recruiting | Phase 2 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | November 27, 2017 | November 20, 2024 |
| NCT03595592 | Active, not recruiting | Phase 3 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | September 7, 2018 | March 15, 2027 |
| NCT03417544 | Active, not recruiting | Phase 2 | Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | May 21, 2018 | December 2025 |
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT02445586 | Completed | Phase 4 | Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer | August 17, 2015 | September 26, 2018 |
| NCT02491892 | Completed | Phase 2 | A Study of Pertuzumab in Participants With Metastatic Breast Cancer | February 2003 | April 2005 |
| NCT02507375 | Completed | Phase 1 | A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | September 2006 | December 2008 |
| NCT02530424 | Completed | Phase 2 | "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " | May 2015 | November 2019 |
| NCT02536339 | Completed | Phase 2 | A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy | December 16, 2015 | December 29, 2020 |
| NCT02586025 | Completed | Phase 3 | Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel | March 14, 2016 | March 14, 2022 |
| NCT02605915 | Completed | Phase 1 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | December 31, 2015 | November 13, 2019 |
| NCT02682693 | Completed | Phase 2 | Denosumab as an add-on Neoadjuvant Treatment (GeparX) | February 13, 2017 | December 31, 2020 |
| NCT02738970 | Completed | Phase 1 | A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) | June 23, 2016 | May 31, 2018 |
| NCT02789657 | Completed | Phase 2 | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | November 21, 2016 | March 27, 2020 |
| NCT02896855 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | September 13, 2016 | January 22, 2021 |
| NCT03112590 | Completed | Phase 1/Phase 2 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | June 23, 2017 | February 20, 2023 |
| NCT03135171 | Completed | Phase 1 | Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | July 26, 2017 | March 20, 2020 |
| NCT01491737 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | February 17, 2012 | November 14, 2019 |
| NCT00096941 | Completed | Phase 2 | A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study | May 2005 | October 2007 |
| NCT00096993 | Completed | Phase 2 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | January 2005 | September 2007 |
| NCT00301899 | Completed | Phase 2 | Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab | December 2005 | October 2007 |
| NCT00545688 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. | June 26, 2006 | September 22, 2014 |
| NCT00551421 | Completed | Phase 1/Phase 2 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | October 2007 | June 2012 |
| NCT00567190 | Completed | Phase 3 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer | February 12, 2008 | November 23, 2018 |
| NCT00833963 | Completed | A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine | January 14, 2009 | April 13, 2017 | |
| NCT00855894 | Completed | Phase 2 | A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer | March 2009 | March 2012 |
| NCT00934856 | Completed | Phase 1/Phase 2 | A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer | July 2009 | October 2013 |
| NCT00943670 | Completed | Phase 2 | Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression | July 2009 | August 2011 |
| NCT00976989 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | November 2009 | January 2016 |
| NCT01026142 | Completed | Phase 3 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | January 26, 2010 | August 7, 2017 |
| NCT01048099 | Completed | N/A | Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer | January 2011 | July 2014 |
| NCT01120184 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) | July 31, 2010 | September 16, 2016 |
| NCT01121939 | Completed | Phase 2 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | May 2010 | August 2015 |
| NCT01461057 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer | December 6, 2011 | October 31, 2017 |
| NCT00063154 | Completed | Phase 2 | Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy | July 2003 | April 2005 |
| NCT01565083 | Completed | Phase 2 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer | April 2012 | October 2015 |
| NCT01572038 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | June 1, 2012 | September 20, 2019 |
| NCT01674062 | Completed | Phase 2 | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer | May 2006 | September 2015 |
| NCT01684878 | Completed | Phase 3 | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | October 22, 2012 | April 28, 2016 |
| NCT01774786 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | June 10, 2013 | December 31, 2019 |
| NCT01835236 | Completed | Phase 2 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | March 3, 2013 | May 26, 2020 |
| NCT01847001 | Completed | Phase 2 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | October 2012 | October 16, 2019 |
| NCT01855828 | Completed | Phase 2 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | September 2013 | August 2018 |
| NCT01875666 | Completed | Early Phase 1 | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | August 5, 2013 | December 19, 2016 |
| NCT01904903 | Completed | Phase 2 | Cardiac Safety Study in Patients With HER2 + Breast Cancer | October 2013 | June 2020 |
| NCT01918254 | Completed | Phase 1 | A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | August 6, 2013 | October 7, 2016 |
| NCT01922921 | Completed | Phase 1/Phase 2 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | February 5, 2014 | September 1, 2021 |
| NCT01959490 | Completed | Phase 2 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | September 24, 2013 | March 29, 2017 |
| NCT01966471 | Completed | Phase 3 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | January 31, 2014 | June 4, 2021 |
| NCT02004093 | Completed | Phase 2 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | December 2005 | September 2008 |
| NCT02019277 | Completed | Phase 3 | A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | December 5, 2013 | November 4, 2016 |
| NCT02060253 | Completed | Phase 1 | Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | April 2014 | June 2018 |
| NCT02073487 | Completed | Phase 2 | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | February 2014 | January 2019 |
| NCT02091141 | Completed | Phase 2 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | April 14, 2014 | May 24, 2023 |
| NCT02125344 | Completed | Phase 3 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | December 2014 | January 30, 2017 |
| NCT02131064 | Completed | Phase 3 | A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | June 25, 2014 | May 29, 2018 |
| NCT02132949 | Completed | Phase 2 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | July 14, 2014 | August 25, 2020 |
| NCT02139358 | Completed | Phase 1/Phase 2 | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | September 5, 2014 | March 16, 2020 |
| NCT02266173 | Completed | Observational Study of Pertuzumab Safety in Participants With Breast Cancer | February 5, 2015 | March 8, 2021 | |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02411344 | Completed | Phase 2 | Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy | February 2014 | January 12, 2018 |
| NCT03644186 | Completed | Phase 2 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | April 16, 2019 | April 14, 2023 |
| NCT03726879 | Completed | Phase 3 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | January 11, 2019 | August 24, 2023 |
| NCT03988036 | Completed | Phase 2 | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | August 18, 2020 | May 31, 2022 |
| NCT04629846 | Completed | Phase 3 | Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. | November 23, 2020 | October 24, 2023 |
| NCT04957212 | Completed | Phase 3 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | August 11, 2018 | May 27, 2020 |
| NCT06439693 | Not yet recruiting | Phase 2 | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | November 2024 | March 30, 2033 |
| NCT06445400 | Not yet recruiting | Phase 2 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | June 2024 | June 2026 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT04337658 | Not yet recruiting | Phase 3 | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | July 1, 2020 | April 30, 2026 |
| NCT05838066 | Not yet recruiting | Phase 3 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | July 2023 | December 2027 |
| NCT05983094 | Not yet recruiting | Phase 2 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | September 1, 2023 | September 1, 2027 |
| NCT04760431 | Not yet recruiting | Phase 2 | TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | October 1, 2021 | September 30, 2025 |
| NCT05720026 | Recruiting | Phase 3 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | January 9, 2023 | February 21, 2026 |
| NCT05786716 | Recruiting | Phase 2/Phase 3 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations | March 7, 2023 | October 2029 |
| NCT04197687 | Recruiting | Phase 2 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | February 20, 2020 | January 15, 2025 |
| NCT03820141 | Recruiting | Phase 2 | Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer | March 3, 2020 | February 2025 |
| NCT04253561 | Recruiting | Phase 1 | Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | February 25, 2020 | August 25, 2025 |
| NCT04266249 | Recruiting | Phase 2 | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | March 13, 2020 | December 31, 2038 |
| NCT04329065 | Recruiting | Phase 2 | Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | April 20, 2022 | June 30, 2027 |
| NCT03412643 | Recruiting | Phase 2 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | May 14, 2018 | October 30, 2023 |
| NCT06278870 | Recruiting | Phase 3 | Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | September 6, 2023 | June 30, 2031 |
| NCT00781612 | Recruiting | Phase 2 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | October 16, 2008 | September 20, 2029 |
| NCT06162559 | Recruiting | Phase 1 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study | December 18, 2023 | May 2036 |
| NCT04551521 | Recruiting | Phase 2 | CRAFT: The NCT-PMO-1602 Phase II Trial | October 13, 2021 | June 30, 2025 |
| NCT04588545 | Recruiting | Phase 1/Phase 2 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | December 10, 2020 | November 1, 2024 |
| NCT06441890 | Recruiting | Phase 2 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer | June 2024 | June 2028 |
| NCT04680442 | Recruiting | Phase 2 | Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction | July 1, 2021 | June 1, 2025 |
| NCT05978648 | Recruiting | Phase 2 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy | September 20, 2023 | December 31, 2027 |
| NCT05900206 | Recruiting | Phase 2 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | October 26, 2023 | April 30, 2032 |
| NCT04993014 | Recruiting | Phase 2 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer | March 1, 2021 | April 30, 2028 |
| NCT05020860 | Recruiting | Phase 2 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | April 18, 2023 | November 2029 |
| NCT05036005 | Recruiting | Phase 4 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) | July 11, 2021 | July 2023 |
| NCT05041842 | Recruiting | Phase 2 | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | December 17, 2021 | March 30, 2026 |
| NCT04193059 | Recruiting | Phase 3 | Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | August 1, 2018 | July 2024 |
| NCT05385705 | Recruiting | Phase 1 | A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 | May 11, 2022 | April 11, 2027 |
| NCT05420467 | Recruiting | Phase 4 | A Study for the Adjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT05883852 | Recruiting | Phase 3 | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | June 7, 2023 | July 1, 2031 |
| NCT01817452 | Recruiting | Phase 2 | A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol | March 2014 | October 2024 |
| NCT05582499 | Recruiting | Phase 1/Phase 2 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | November 1, 2022 | September 2025 |
| NCT05638594 | Recruiting | Phase 2 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | December 20, 2022 | December 10, 2027 |
| NCT05656079 | Recruiting | N/A | To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study | July 1, 2021 | September 2025 |
| NCT05420454 | Recruiting | Phase 4 | A Study for the Neoadjuvant Treatment of Breast Cancer | July 10, 2022 | December 20, 2027 |
| NCT05132582 | Recruiting | Phase 3 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | March 7, 2022 | June 30, 2027 |
| NCT05180006 | Recruiting | Phase 2 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | February 24, 2022 | February 2026 |
| NCT05188313 | Recruiting | Phase 3 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | March 9, 2022 | February 2037 |
| NCT05891561 | Recruiting | Phase 2 | Short-course Trastuzumab, Pertuzumab With Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | November 1, 2023 | December 2026 |
| NCT05319873 | Recruiting | Phase 1/Phase 2 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | April 7, 2022 | April 1, 2026 |
| NCT05323955 | Recruiting | Phase 2 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | March 23, 2023 | October 2027 |
| NCT05325632 | Recruiting | Phase 2 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | October 28, 2021 | January 31, 2025 |
| NCT04419181 | Suspended | Phase 2 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | August 11, 2024 | June 1, 2026 |
| NCT00947167 | Terminated | Phase 2 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | March 2009 | May 2010 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT03894007 | Terminated | Phase 2 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer | May 23, 2019 | June 30, 2021 |
| NCT04108858 | Terminated | Phase 1/Phase 2 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | May 20, 2021 | April 29, 2022 |
| NCT02598427 | Terminated | Phase 1 | Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | May 1, 2017 | February 22, 2018 |
| NCT02593708 | Terminated | Phase 1 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | November 3, 2015 | July 31, 2017 |
| NCT02480010 | Terminated | Phase 2 | A Study of Pertuzumab in Participants With Prostate Cancer | September 2003 | September 2005 |
| NCT02379585 | Terminated | Phase 1/Phase 2 | Fasting on Newly Diagnosed Breast Cancer | January 2013 | August 2015 |
| NCT02229149 | Terminated | Phase 2 | Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | December 2014 | January 2022 |
| NCT01912963 | Terminated | Phase 2 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | September 2013 | December 2016 |
| NCT01108458 | Terminated | Phase 2 | A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | July 2010 | March 2011 |
| NCT03329378 | Terminated | Phase 2 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | January 24, 2019 | March 7, 2021 |
| NCT05429684 | Unknown status | Phase 3 | Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer | January 1, 2021 | February 28, 2024 |
| NCT03264547 | Unknown status | Phase 3 | A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | August 28, 2017 | October 31, 2023 |
| NCT03144947 | Unknown status | Phase 2 | Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients | November 29, 2016 | November 2021 |
| NCT01850628 | Unknown status | NSABP Biospecimen Discovery Project | July 2013 | February 2022 | |
| NCT04717531 | Unknown status | Phase 2 | Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer | June 3, 2021 | May 31, 2024 |
| NCT04683445 | Unknown status | Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer | December 1, 2020 | December 31, 2023 | |
| NCT04514419 | Unknown status | Phase 3 | Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel | June 30, 2020 | November 20, 2021 |
| NCT02514681 | Unknown status | Phase 3 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer | August 1, 2015 | December 2021 |
| NCT02689921 | Unknown status | Phase 2 | NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer | April 2016 | December 2018 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT02336984 | Withdrawn | Phase 1/Phase 2 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | June 2014 | April 4, 2016 |
| NCT03811418 | Withdrawn | Phase 3 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | January 2019 | April 2019 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Perjeta
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2012
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2013
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Her2**
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 乳がん